

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

_					
	APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
	10/626,415	07/23/2003	Karl H. Weisgraber	UCAL-282	2272
	24353 7590 12/26/2006 BOZICEVIC, FIELD & FRANCIS LLP 1900 UNIVERSITY AVENUE		EXAMINER		
				SRIVASTAVA, KAILASH C	
	SUITE 200 EAST PALO A	ALTO, CA 94303	·	ART UNIT	PAPER NUMBER
		,		1657	-
				MAIL DATE	DELIVERY MODE
				12/26/2006	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

Application No. Applicant(s) 10/626,415 WEISGRABER ET AL. Interview Summary Examiner **Art Unit** Kailash Srivastava 1657 All participants (applicant, applicant's representative, PTO personnel): (1) Jon P. Weber, Ph.D.. (2) Paula Gordon. Date of Interview: 18 December 2006. Type: a) ☐ Telephonic b) ☐ Video Conference c) Personal [copy given to: 1) applicant 2) applicant's representative Exhibit shown or demonstration conducted: d) Yes e) No. If Yes, brief description: ____. Claim(s) discussed: 1-4 and 21. Identification of prior art discussed: Morrow et al. 2000; Barrick et al. 1993. Agreement with respect to the claims f) \boxtimes was reached. g) \square was not reached. h) \square N/A. Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: See Continuation Sheet. (A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.) THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN A NON-EXTENDABLE PERIOD OF THE LONGER OF ONE MONTH OR THIRTY DAYS FROM THIS

INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO

FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview

tachment: 892 & Ref

requirements on reverse side or on attached sheet.

Examiner Note: You must sign this form unless it is an

Attachment to a signed Office action.

Examinér's signature, if required

Continuation of Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: Attorney requested more explanation of 112, 1st rejections under written description and enablement. Explained that I am asking examiners to directly address the factors in both cases, from the wirtten description guidelines and from In re Wands respectively. Explained to the attorney how the examiner was trying to address these factors. We discussed the nutshell questions, "Are they in possession of the genus of all ApoE stable folding intermediates?", and "Do they adequately teach how to make and use the genus of ApoE stable folding intermediates?" Applicants have provided evidence of producing a high percentage of a folding intermediate under specific conditions of urea and pH for two species, human full length ApoE4 and a 22 kD fragment of ApoE3 and ApoE4. This folding intermediate is said to be consistent with the three state model of Barrick et al. 1993 (mentioned in the specification, but not of record), and to have at least some characteristics consistent with the molten globule model of protein folding. We looked at Figures 1 and 2 in particular which show a shoulder in the elipticity consistent with a folding intermediate. This is a limited showing considering the breadth of claims. ApoE is widespread among vertebrates, for example.